1. Home
  2. HHH vs NAMS Comparison

HHH vs NAMS Comparison

Compare HHH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$72.05

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.30

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHH
NAMS
Founded
2010
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
HHH
NAMS
Price
$72.05
$35.30
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$90.00
$46.75
AVG Volume (30 Days)
414.0K
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$1,474,892,000.00
N/A
Revenue This Year
$14.04
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
$515.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.01
$20.53
52 Week High
$91.07
$42.21

Technical Indicators

Market Signals
Indicator
HHH
NAMS
Relative Strength Index (RSI) 61.44 57.72
Support Level $61.79 $33.83
Resistance Level $86.24 $37.27
Average True Range (ATR) 1.60 1.74
MACD 0.04 0.42
Stochastic Oscillator 63.22 71.19

Price Performance

Historical Comparison
HHH
NAMS

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: